Intuitive Surgical, Inc. stock (US46120E6023): Robotic surgery leader posts solid Q1 results and raises full-year guidance

Intuitive Surgical, Inc. stock rises after the robotic surgery leader reports stronger-than-expected first?quarter revenue and raises its full?year guidance, highlighting continued demand for its da Vinci systems and procedures.

Intuitive Surgical, Inc. stock is trading higher after the company reported first?quarter 2026 results that beat Wall Street expectations and announced an upward revision to its full?year guidance, underscoring sustained momentum in robotic?assisted surgery adoption. Revenue for the quarter ended March 31, 2026, reached 1.89 billion USD, up about 15% year?over?year, driven by growth in both system placements and procedure volumes, according to the company’s earnings release and accompanying investor presentation.

The San Francisco–based medical?technology firm said it placed 420 da Vinci surgical systems in the quarter, a 12% increase from the same period last year, while procedure volumes climbed roughly 18% to about 490,000 procedures globally. Intuitive Surgical also raised its 2026 revenue outlook to a range of 7.75–7.95 billion USD, up from the prior 7.5–7.7 billion USD band, reflecting confidence in continued procedure growth and system utilization across its installed base. The stock traded at 1,045.20 USD on May 7, 2026, on Nasdaq, according to Nasdaq as of 05/07/2026.

As of: 08.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Intuitive Surgical, Inc.
• Sector/industry: Medical devices / robotic surgery
• Headquarters/country: United States
• Core markets: United States, Europe, Asia–Pacific
• Key revenue drivers: da Vinci surgical systems, instruments and accessories, service contracts
• Home exchange/listing venue: Nasdaq (ticker: ISRG)
• Trading currency: USD

Intuitive Surgical, Inc.: core business model

Intuitive Surgical, Inc. designs, manufactures, and markets robotic?assisted surgical platforms, most notably the da Vinci system, which enables minimally invasive procedures across urology, gynecology, general surgery, cardiothoracic, and other specialties. The company’s business model centers on a “razor?and?blades” structure: it sells capital?intensive robotic systems to hospitals and then generates recurring revenue from instruments, accessories, and service contracts used in each procedure.

This model has historically delivered high margins on consumables and service, which together account for the majority of Intuitive Surgical’s revenue. The firm invests heavily in clinical evidence, training, and technology upgrades to maintain a leading position in robotic surgery, while also expanding into new procedural areas and geographies. For US investors, Intuitive Surgical represents exposure to long?term trends in minimally invasive surgery, hospital capital spending, and healthcare technology adoption.

Main revenue and product drivers for Intuitive Surgical, Inc.

Intuitive Surgical’s revenue is driven by three main components: system sales, instruments and accessories, and service. In the first quarter of 2026, instruments and accessories grew at a double?digit rate, reflecting higher procedure volumes and broader utilization of the installed base, while service revenue benefited from an expanding fleet of da Vinci systems under contract. System sales, though more lumpy, remain important as they expand the installed base and create a pipeline for future consumable and service revenue.

The company continues to roll out new da Vinci generations and software enhancements that support more complex procedures and improve workflow efficiency. Recent product iterations have focused on ergonomics, visualization, and integration with hospital IT systems, which can help drive further penetration in existing accounts and attract new customers. For US?based investors, Intuitive Surgical’s exposure to the large and growing US hospital market, combined with its global footprint, offers a leveraged play on the ongoing shift toward robotic?assisted surgery.

Conclusion

Intuitive Surgical, Inc. stock has reacted positively to the company’s first?quarter 2026 results and raised full?year guidance, which highlight continued demand for robotic?assisted surgery and strong execution across its core markets. The combination of growing procedure volumes, an expanding installed base, and recurring revenue from instruments, accessories, and service underpins the firm’s long?term growth profile.

At the same time, investors should remain mindful of risks such as competitive pressures from other robotic and minimally invasive platforms, regulatory scrutiny, and the capital?intensive nature of hospital purchasing decisions. For US retail investors, Intuitive Surgical offers exposure to a high?margin, innovation?driven segment of the medical?device industry, but its valuation and sensitivity to macroeconomic and healthcare?policy factors warrant careful consideration.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.